Trial Profile
A Phase II Study of Implants of Encapsulated Human NTC-201 Cells Releasing Ciliary Neurotrophic Factor (CNTF), in Participants With Visual Acuity Impairment Associated With Atrophic Macular Degeneration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs NT 501 (Primary)
- Indications Dry macular degeneration
- Focus Therapeutic Use
- Sponsors GNT Pharma
- 31 Oct 2014 New trial record